Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $239.3 million.

  • Catalyst Pharmaceuticals' Free Cash Flow fell 55.33% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $234.5 million, marking a year-over-year increase of 4.70%. This contributed to the annual value of $239.3 million for FY2024, which is 66.88% up from last year.
  • Catalyst Pharmaceuticals' Free Cash Flow amounted to $239.3 million in FY2024, which was up 66.88% from $143.4 million recorded in FY2023.
  • Catalyst Pharmaceuticals' Free Cash Flow's 5-year high stood at $239.3 million during FY2024, with a 5-year trough of $45.0 million in FY2020.
  • In the last 3 years, Catalyst Pharmaceuticals' Free Cash Flow had a median value of $143.4 million in 2023 and averaged $166.2 million.
  • Data for Catalyst Pharmaceuticals' Free Cash Flow shows a peak YoY spiked of 95.48% (in 2022) over the last 5 years.
  • Over the past 5 years, Catalyst Pharmaceuticals' Free Cash Flow (Yearly) stood at $45.0 million in 2020, then skyrocketed by 31.82% to $59.4 million in 2021, then surged by 95.48% to $116.0 million in 2022, then increased by 23.57% to $143.4 million in 2023, then spiked by 66.88% to $239.3 million in 2024.